HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eddingpharm International Holdings Ltd.

www.eddingpharm.com

Latest From Eddingpharm International Holdings Ltd.

China Coronavirus Cases Up Sharply As Pharma Rushes To Aid

AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.

China Risk Management

Vascepa Included In European Dyslipidemia Guidelines Ahead Of Approval

Amarin won't seek approval in the EU until later this year, but doctors there are encouraged to consider Vascepa for patients with high triglycerides despite statin therapy. Also, PCSK9 inhibitor guidelines were solidified for very high risk patients.

Cardiovascular Regulation

Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?

Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.

China Generic Drugs

Amarin Will Double Vascepa Sales Team In Big Bet On Supplemental Approval

Anticipating a label expansion this fall based on the REDUCE-IT cardiovascular outcomes study, Amarin will double its sales force and has raised revenue guidance. Approved to reduce very high triglyceride levels, Vascepa sales total $170m-$174m so far this year.

Life Cycle Management Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Eddingpharm (Cayman) Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Hong Kong
  • Parent & Subsidiaries
  • Eddingpharm International Holdings Ltd.
  • Senior Management
  • Xin Ni, Chmn. & CEO
    Guili Miao, CFO
  • Contact Info
  • Eddingpharm International Holdings Ltd.
    Phone: (852) 37550555
    Ste. 3306, 33rd Fl., Tower 6
    The Gateway Harbor City,
    Hong Kong
UsernamePublicRestriction

Register